BIO, Two Drugmakers Side With Amgen in Biosimilar Case

Drug Industry Daily
An industry group and two drugmakers have filed U.S. Supreme Court briefs backing Amgen’s request that a Federal Circuit ruling be partially affirmed to mandate that biosimilar makers share information and wait six months after an FDA approval to launch a therapy.

To View This Article:


Subscribe To Drug Industry Daily